Novozymes A S – ADR (NASDAQ:NVZMY) target price raised to $48.00, issued a report today by Zacks Investment Research
- Updated: October 14, 2016
Yesterday Novozymes A S – ADR (NASDAQ:NVZMY) traded 0.40% higher at $42.59. The company’s 50-day moving average is $43.60 and its 200-day moving average is $46.02. The last closing price is down -7.46% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 11,961 shares of the stock were exchanged, down from an average trading volume of 20,451
Novozymes A S – ADR (NASDAQ:NVZMY) had its target price raised to $48.00 by Zacks Investment Research in a report released 10/15/2016. The new target price indicates a possible upside of 0.13% based on the company's last closing price.
See Chart Below
Novozymes A S – ADR has a 52 week low of $37.98 and a 52 week high of $49.55 with a P/E ratio of 29.78 Novozymes A S – ADR’s market capitalization is presently $0.
General Company Details For Novozymes A S – ADR (NASDAQ:NVZMY)
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. In June 2013, the Company restructured its sales areas within those segments. The Household Care (old Household Care Enzymes) area comprises cleaning solutions, laundry, dishwashing and microorganism sales for cleaning solutions. The Food & Beverages (old Food & Beverages Enzymes) manufactures enzymes for the food industry. The Bioenergy (old Bioenergy Enzymes) provides enzymes to the energy industry. The Agriculture & Feed area combines old Feed & Other Technical Enzymes area (enzymes sales to the feed industry) and microorganism sales for aquaculture and agriculture. The Technical & Pharma area combines old Feed & Other Technical Enzymes area (enzymes to other technical industries), microorganism sales for wastewater treatment, and Biopharma (recombinant ingredients and technologies).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.